Role of Ca\(^{2+}\) in the Control of H\(_{2}\)O\(_{2}\)-Modulated Phosphorylation Pathways Leading to eNOS Activation in Cardiac Myocytes

Citation

Published Version
doi:10.1371/journal.pone.0044627

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10589803

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Role of Ca\textsuperscript{2+} in the Control of H\textsubscript{2}O\textsubscript{2}-Modulated Phosphorylation Pathways Leading to eNOS Activation in Cardiac Myocytes

Juliano L. Sartoretto\textsuperscript{1,*}, Hermann Kalwa\textsuperscript{1}, Takashi Shiroto\textsuperscript{1}, Simone M. Sartoretto\textsuperscript{1}, Michael D. Pluth\textsuperscript{2}, Stephen J. Lippard\textsuperscript{2}, Thomas Michel\textsuperscript{1,\#}

\textsuperscript{1}Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
\textsuperscript{2}Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America

Abstract

Nitric oxide (NO) and hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) play key roles in physiological and pathological responses in cardiac myocytes. The mechanisms whereby H\textsubscript{2}O\textsubscript{2}-modulated phosphorylation pathways regulate the endothelial isoform of nitric oxide synthase (eNOS) in these cells are incompletely understood. We show here that H\textsubscript{2}O\textsubscript{2} treatment of adult mouse cardiac myocytes leads to increases in intracellular Ca\textsuperscript{2+} ([Ca\textsuperscript{2+}]\textsubscript{i}), and document that activity of the L-type Ca\textsuperscript{2+} channel is necessary for the H\textsubscript{2}O\textsubscript{2}-promoted increase in sarcomere shortening and of [Ca\textsuperscript{2+}]\textsubscript{i}. Using the chemical NO sensor Cu\textsubscript{2+}(FL2E), we discovered that the H\textsubscript{2}O\textsubscript{2}-promoted increase in cardiac myocyte NO synthesis requires activation of the L-type Ca\textsuperscript{2+} channel, as well as phosphorylation of the AMP-activated protein kinase (AMPK), and mitogen-activated protein kinase kinase kinase 1/2 (MEK1/2). Moreover, H\textsubscript{2}O\textsubscript{2}-stimulated phosphorylations of eNOS, AMPK, MEK1/2, and ERK1/2 all depend on both an increase in [Ca\textsuperscript{2+}]\textsubscript{i}, as well as the activation of protein kinase C (PKC). We also found that H\textsubscript{2}O\textsubscript{2}-promoted cardiac myocyte eNOS translocation from peripheral membranes to internal sites is abrogated by the L-type Ca\textsuperscript{2+} channel blocker nifedipine. We have previously shown that kinase Akt is also involved in H\textsubscript{2}O\textsubscript{2}-promoted eNOS phosphorylation. Here we present evidence documenting that H\textsubscript{2}O\textsubscript{2}-promoted Akt phosphorylation is dependent on activation of the L-type Ca\textsuperscript{2+} channel, but is independent of PKC. These studies establish key roles for Ca\textsuperscript{2+}- and PKC-dependent signaling pathways in the modulation of cardiac myocyte eNOS activation by H\textsubscript{2}O\textsubscript{2}.

Introduction

The endothelial isoform of nitric oxide synthase (eNOS) is robustly expressed in cardiac myocytes, and nitric oxide (NO) has been shown to play key roles in modulating cardiac function [1,2,3]. eNOS is a Ca\textsuperscript{2+}/calmodulin-dependent enzyme that undergoes phosphorylation on multiple residues in response to extracellular stimuli, involving several protein kinases and phosphoprotein phosphatases. We have recently shown that hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}) is a critical intracellular mediator that modulates eNOS phosphorylation and enzyme activation in cardiac myocytes [2]. However, the role of H\textsubscript{2}O\textsubscript{2} in modulation of cardiac myocyte Ca\textsuperscript{2+} metabolism is less well understood, and there are major gaps in our understanding of the pathways connecting H\textsubscript{2}O\textsubscript{2}-dependent phosphorylation pathways, intracellular Ca\textsuperscript{2+} signaling, and eNOS activation.

Cardiac myocytes contain an astonishingly broad array of protein kinases, several of which may be modulated by H\textsubscript{2}O\textsubscript{2}. Some protein kinase C (PKC) isoforms are activated by H\textsubscript{2}O\textsubscript{2}, yet little is known about the modulation of eNOS by PKC in the heart. Other protein kinases expressed in cardiac myocytes that have been implicated in eNOS regulation include ERK1/2, MEK1/2, kinase Akt, AMPK, and the cyclic AMP-dependent protein kinase (PKA). Since abnormalities in PKC-modulated signaling pathways and alterations in intracellular Ca\textsuperscript{2+} metabolism have been implicated in cardiomyopathy and heart failure [4,5,6], we decided to explore the role of H\textsubscript{2}O\textsubscript{2} in control of PKC activation, intracellular Ca\textsuperscript{2+} pathways, and eNOS phosphorylation responses in cardiac myocytes. Here we provide data that establish roles for Ca\textsuperscript{2+}, PKC and PKA in modulating eNOS phosphorylation in response to H\textsubscript{2}O\textsubscript{2}, and identify the key protein kinase pathways that modulate H\textsubscript{2}O\textsubscript{2}-dependent NO synthesis in cardiac myocytes.
**Results**

The fluorescent Ca\(^{2+}\) indicator Fura-2 was used to measure [Ca\(^{2+}\)], in electrically stimulated (1 Hz, 5–10 volts) cardiac myocytes that had been freshly isolated from adult mice. We found that H\(_2\)O\(_2\) (25 \(\mu\)M) promotes an increase in [Ca\(^{2+}\)], measured as the ratio of F\(_{340}/F_{380}\) (Figure 1A). We next treated cardiac myocytes with nifedipine, an extensively characterized L-type Ca\(^{2+}\) channel-blocking drug, to probe the role of L-type Ca\(^{2+}\) channels in the H\(_2\)O\(_2\)-stimulated responses observed in these cells. As shown in Figure 1A, the H\(_2\)O\(_2\)-promoted increase in cell-derived Fura-2 fluorescence is blocked by nifedipine. Similarly, the H\(_2\)O\(_2\)-promoted increase in cardiac myocyte contractility is abrogated by pre-treatment of the cells with nifedipine (Figure 1B). We also performed experiments comparing H\(_2\)O\(_2\)- and isoproterenol-promoted changes both in [Ca\(^{2+}\)], and cardiac myocyte contractility. As shown in Figures 1C and 1D, the magnitude of both the H\(_2\)O\(_2\)-promoted contractility and Ca\(^{2+}\) responses are ~70% of the responses seen following treatment with the \(\beta\)-adrenergic agonist isoproterenol.

Figure 2 presents the results of experiments using the NO chemical sensor Cu\(_2\)(FL2E), which we previously used to explore the agonist-modulated regulation of cardiac myocyte NO synthesis [2]. H\(_2\)O\(_2\)-promoted NO synthesis is completely blocked by pre-treatment of the cells with nifedipine (100 \(\mu\)M, 30 min) (Figure 2A). Nifedipine also abrogates the H\(_2\)O\(_2\)-promoted increase in eNOS phosphorylation (Figure 2B). The intracellular Ca\(^{2+}\) chelator BAPTA-AM blocks the H\(_2\)O\(_2\)-promoted increase in eNOS phosphorylation (Figure 2C). We previously demonstrated that H\(_2\)O\(_2\) treatment of cardiac myocytes promotes reversible eNOS translocation from peripheral to internal membranes and back [2]. Figure 2D shows that H\(_2\)O\(_2\)-promoted eNOS translocation is completely blocked by nifedipine, without affecting the localization of the scaffolding/regulatory protein caveolin-3. Under these conditions, there is no change in total eNOS protein abundance in these cells, nor is there any apoptosis or necrosis of these cells (Figure 2A, F, and D).

We next investigated the H\(_2\)O\(_2\)-stimulated Ca\(^{2+}\)-modulated phosphorylation pathways regulating eNOS responses in these cells. As shown in Figure 3A, nifedipine blocks the H\(_2\)O\(_2\)-promoted increase in PKC phosphorylation. Because adult mouse cardiac myocytes are not amenable to RNA interference approaches, we used a series of protein kinase inhibitors to probe the pathways connecting H\(_2\)O\(_2\) with eNOS phosphorylation. We found that the PKC inhibitor calphostin C blocks the increase in eNOS and PKC phosphorylations promoted by H\(_2\)O\(_2\) (Figure 3B). We selected for analysis of eNOS phosphorylation the major band at M, 135 kDa, which is the same M as the band seen in the total eNOS immunoblot. For PKC, the multiple bands seen may reflect the fact that we are using a “pan-phospho-PKC” antibody that picks up several different phospho-PKC isoforms; quantification of phospho-PKC includes all bands migrating in the vicinity of known PKC isoforms.

We previously found [2] that the H\(_2\)O\(_2\) promoted increase in eNOS phosphorylation depends on the AMP-activated protein kinase (AMPK). Here we show that the AMPK inhibitor Compound C blocks H\(_2\)O\(_2\)-induced cardiac myocyte NO synthesis, measured with the NO chemical sensor Cu\(_2\)(FL2E) (Figure 4A). In order to investigate the role of L-type Ca\(^{2+}\) channel on the H\(_2\)O\(_2\)-promoted increase in AMPK phosphorylation, we analyzed immunoblots performed in cardiac myocyte lysates prepared from cells incubated with nifedipine (100 \(\mu\)M, 30 min) prior to H\(_2\)O\(_2\) treatment (25 \(\mu\)M, 15 min) (Figure 4B). Nifedipine abrogates both the increase in AMPK phosphorylation as well as phosphorylation of the well-known AMPK substrate protein, acetyl-CoA carboxylase (ACC). The intracellular Ca\(^{2+}\) chelator BAPTA-AM also blocks H\(_2\)O\(_2\)-promoted AMPK and ACC phosphorylation (Figure 4C). Importantly, the PKC inhibitor calphostin C blocks H\(_2\)O\(_2\)-stimulated phosphorylation of AMPK and ACC (Figure 4D). H\(_2\)O\(_2\) also promotes phosphorylation of the protein kinases MEK1/2 and ERK1/2 (Figure 5A) and also attenuates the MEK1/2 and ERK1/2 phosphorylation responses are abrogated by nifedipine, BAPTA, or calphostin C (Figure 6). The phosphorylation response of kinase Akt to H\(_2\)O\(_2\) appears to be differentially regulated: while H\(_2\)O\(_2\)-promoted Akt phosphorylation is blocked by nifedipine and BAPTA (as found for eNOS, AMPK, ERK1/2, and MEK1/2), calphostin C fails to attenuate Akt phosphorylation (Figure 6C). In contrast, the H\(_2\)O\(_2\)-stimulated phosphorylation of these other kinases is blocked by calphostin C (Figures 3B, 4D, and 6C). Moreover, H\(_2\)O\(_2\)-stimulated AMPK and Akt phosphorylations are unaffected by MAP kinase pathway inhibitors (Figure 6B and C). We next explored the role of PKA by investigating the effects of H\(_2\)O\(_2\) on the phosphorylation of the protein VASP [1]. We probed immunoblots with phosphospecific antibodies directed against VASP phosphoserine 157, the
Figure 2. Nifedipine effects on H2O2-promoted NO synthesis, eNOS phosphorylation, and eNOS translocation. In Panel A, mouse cardiac myocytes were loaded with the NO chemical sensor Cu2(FL2E), and then treated with nifedipine (100 μM) or vehicle followed by hydrogen peroxide (H2O2, 10 μM) treatment. Upper panel shows representative fluorescence images at 0, 2, and 5 minutes following treatments as indicated. Middle panel shows representative fluorescence tracings of single cells treated with H2O2 or H2O2 in the presence of nifedipine. Lower panel shows the results of pooled data analyzed from at least three independent repetitions with a minimum of 4 cells analyzed per experiment that yielded equivalent results; *indicates p<0.05. In Panel B, cardiac myocytes were incubated with nifedipine (100 μM, 30 min) or vehicle, then treated with hydrogen peroxide (H2O2, 25 μM, 15 min) and analyzed in immunoblots probed with antibodies as shown. Panel C shows immunoblot analyses from cardiac myocytes incubated with the intracellular calcium chelator BAPTA AM (60 μM, 30 min) or vehicle, then treated with H2O2 (25 μM, 15 min). Below each representative immunoblot the results of densitometric analyses from pooled data are shown, documenting the changes in phospho-eNOS1177 and phospho-eNOS633 plotted relative to the signals present in unstimulated cells. Each data point represents the mean ± S.E. derived from at least three independent experiments; *indicates p<0.05 (ANOVA). Panel D shows confocal microscopic images of cardiac myocytes treated with nifedipine (100 μM, 30 min) or vehicle, then treated with H2O2 (10 μM) for the indicated times. The cells were fixed, permeabilized, and probed with antibodies against total caveolin-3 (Alexa Fluor-Red 568) or eNOS (Alexa Fluor-Green 488); overlapping signals are shown in yellow. The bar graph below shows pooled data from three experiments, quantitating the percent overlap between eNOS and caveolin-3 at different times after adding H2O2. *indicates p<0.03 compared to t=0.

doi:10.1371/journal.pone.0044627.g002

Discussion

These studies have used a combination of cellular imaging and biochemical approaches to explore eNOS activation and phosphorylation pathways in isolated mouse cardiac myocytes treated with H2O2. Several previous reports on the effects of ROS in cardiac myocytes have studied higher H2O2 concentrations and more prolonged treatments, which can lead to oxidative stress, Ca2+ overload, and myocyte apoptosis or necrosis [7,8]. However, it is unlikely that the short-term exposure to low concentrations of H2O2 used in the present study cause cardiac myocyte membrane damage (Figure S1F); instead, our findings suggest a physiological role for H2O2 in the modulation of myocyte L-type Ca2+ channels. We found that H2O2-promoted increases in eNOS phosphorylation, NO production, and changes in eNOS subcellular localization in cardiac myocytes require L-type Ca2+ channel activity. Several lines of evidence in this study implicate Ca2+- and PKC-dependent signaling pathways as upstream determinants of H2O2-promoted responses in cardiac myocytes. We found that H2O2 treatment leads to increases in [Ca2+]i, in electrically stimulated cardiac myocytes, associated with an increase in myocyte contractility (Figure 1). These findings are in agreement with previous reports [9,10]. Recent studies looking at H2O2-modulated calcium metabolism in cardiac myocytes have identified SERCA and NCX as important targets for H2O2 in these cells [11]. Our studies provide strong evidence for the involvement of L-type Ca2+ channels in modulating cardiac myocyte responses to H2O2.

Using the highly sensitive fluorescent probe Cu2(FL2E) to visualize NO synthesis in cardiac myocytes, we demonstrated that the L-type Ca2+ channel activity is required for H2O2-promoted NO synthesis (Figure 2A). We have previously shown that H2O2 activates the endothelial isoform of NOS in cardiac myocytes [2]. eNOS is a phosphoprotein that undergoes phosphorylation on multiple residues [12]. Here, we found that the increase in eNOS phosphorylation at serine 1177 and 633 residues caused by H2O2 exposure of cardiac myocytes was blocked by nifedipine or BAPTA-AM (Figure 2B and 2C). Because eNOS undergoes intracellular translocation following H2O2 treatment [2], we investigated the role of L-type Ca2+ channel on H2O2-promoted changes in eNOS intracellular localization. Caveolin-3 is a marker for the microdomains known as plasmalemmal caveolae. In cardiac myocytes caveolin-3 is also a binding partner of eNOS [13,14]. As shown in Figure 2D, the colocalization between eNOS and caveolin-3 decreases 15 to 30 minutes after the addition of H2O2; eNOS returns to peripheral membranes and starts to re-localize with caveolin-3 ~60 minutes after the addition of H2O2. Importantly, nifedipine abrogates H2O2-promoted eNOS translocation. There is no change in eNOS abundance or cardiac myocyte viability following treatment with H2O2 under these conditions (Figure S1A). Taken all together, these findings reveal that the H2O2-promoted increases in NO synthesis and eNOS phosphorylation depend on L-type Ca2+ channel activity and are associated with dynamic eNOS translocation.

Several protein kinases phosphorylate eNOS [12], including PKC, which stimulates NO production in endothelial cells associated with increased eNOS phosphorylation [15,16]. In cultured cardiac myocytes, PKC isoforms regulate contractility and hypertrophy [17]. Activation of classical PKC isoforms is modulated by Ca2+ and diacylglycerol [18,19]. We found that exposure to H2O2 leads to an increase in PKC phosphorylation, and confirmed that blockade of the L-type Ca2+ channel by nifedipine abrogates the phosphorylation response (Figure 3A). Inhibition of PKC using calphostin C blocked H2O2-promoted increase in eNOS phosphorylation (Figure 3B). These lines of evidence point to a central role for Ca2+- and PKC-dependent pathways in modulating H2O2-mediated eNOS activation, and are consistent with our finding that H2O2-dependent NO synthesis is blocked in cardiac myocytes treated with nifedipine.

The AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase that has been characterized as a sensor of cellular energy balance in mammalian cells [20]. We and others have previously reported that AMPK regulates eNOS in endothelial cells [21,22]. Using the NO sensor Cu2(FL2E), we demonstrate here that activation of AMPK is required for the H2O2-promoted increase in cardiac myocyte NO synthesis (Figure 4A). Similar to eNOS, H2O2-promoted AMPK activation is Ca2+ and PKC dependent (Figure 4B, 4C, and 4D). Nifedipine treatment of cardiac myocytes not only abrogates the increase in AMPK phosphorylation but also blocks phosphorylation of its substrate ACC (Figure 4B). A23187 calcium ionophore and phorbol 12-myristate 13-acetate treatments of cardiac myocytes enhanced AMPK phosphorylation (Figures 7B and 7C). These findings are consistent with previous observations in other experimental systems suggesting that AMPK can be activated by Ca2+/calmodulin [23]. In addition to AMPK, MEK1/2 appears to be necessary for the H2O2-promoted increase in cardiac

Preferred site for PKA-catalyzed VASP phosphorylation, as can be seen in Figure 7A. H2O2 promotes VASP phosphorylation, and the PKA inhibitor H89 completely blocks this phosphorylation response. Importantly, H2O2-promoted eNOS phosphorylation at ser1177 is blocked by this same PKA inhibitor (Figure 7A). Both calcium ionophore A23187 and the PKC agonist phorbol 12-myristate 13-acetate promote phosphorylation responses in these cells (Figure 7B and C).

Ca2+ and H2O2 in Control of Cardiac Myocyte eNOS

PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e44627
myocyte NO synthesis and eNOS phosphorylation (Figure 5). Although both AMPK and kinase Akt are known to directly phosphorylate eNOS, the mechanisms whereby MEK1/2 and ERK1/2 modulate eNOS phosphorylation and activation are less clearly understood. Clearly, the modulation of cardiac myocyte eNOS by H2O2 involves complex interactions implicating multiple protein kinase pathways (Figure 8).

We have previously shown that both the PI3-K inhibitor wortmannin and Akt inhibitor XI block H2O2-promoted eNOS phosphorylation, and we also found that these inhibitors do not attenuate H2O2-promoted AMPK phosphorylation [2]. On the other hand, inhibition of AMPK by compound C reduces the H2O2-promoted increase in Akt phosphorylation, suggesting that AMPK may lie upstream of Akt in cardiac myocytes, as previously shown in vascular endothelial cells [21]. The inhibition of H2O2-promoted eNOS phosphorylation by the PKA inhibitor H89 (Figure 7A) implicates a role for PKA in modulating the response to H2O2; this hypothesis is further supported by our finding that H2O2 promotes VASP phosphorylation at a serine residue that is preferentially targeted by PKA (Figure 7A). The current studies have also explored whether changes in [Ca2+], or PKC activity are involved in the H2O2-promoted increase in cardiac myocyte Akt phosphorylation. Nifedipine and BAPTA abrogate the H2O2-promoted increase in Akt phosphorylation (Figure 6A and B). These observations are consistent with previous reports in other cell systems, which suggested that PI3-K/Akt can be activated by intracellular Ca2+ fluxes in endothelial cells [24]. Importantly, the H2O2-promoted increase in Akt phosphorylation is unaffected by the PKC inhibitor calphostin C, indicating that signaling to Akt by H2O2 does not involve PKC activation (Figure 6C).

The present studies define a critical role for L-type Ca2+ channel activity in the control of H2O2-dependent pathways that lead to the phosphorylation of protein kinases regulating eNOS signaling in cardiac myocytes. The physiological effects of low H2O2 concentrations seen in these studies can be contrasted to the much higher levels of oxidative stress that have been observed in cardiac disease states, including heart failure and cardiomyopathy [25,26,27]. A deeper understanding of the factors that modulate H2O2 metabolism in cardiac myocytes is needed in order to devise therapeutic strategies to regulate ROS balance in physiological and pathophysiological states in the heart.

Figure 3. Effects of calphostin C on H2O2-promoted eNOS phosphorylation. In panel A, cardiac myocytes were incubated with nifedipine (100 μM, 30 min) or vehicle, then treated with H2O2 (25 μM) and analyzed in immunoblots probed with phospho-protein kinase C (PKC) phosphorylation (I β Ser660) or GAPDH antibodies. Panel B shows a representative experiment looking at the effects of calphostin C on H2O2-promoted eNOS phosphorylation. Freshly isolated adult murine cardiac myocytes were treated with calphostin C (1 μM, 30 min) or vehicle before treatment with H2O2 (25 μM, 15 min). Cell lysates were resolved by SDS-PAGE and probed using antibodies directed against phospho-eNOS Ser1177, phospho-eNOS Ser633, total eNOS, phospho-PKC, or GAPDH. Densitometric analyses from pooled data, plotting the fold increase of the degree of protein phosphorylation (in arbitrary units) relative to the signals present in unstimulated cardiac myocytes are also shown in this figure. Each data point represents the mean ± S.E. derived from three independent experiments, *indicates p<0.05 for respective phospho-protein versus unstimulated cells (ANOVA).

doi:10.1371/journal.pone.0044627.g003
**Materials and Methods**

**Materials**

Polyclonal antibodies directed against phospho-eNOS (Ser1177), phospho-PKC (pan) (BII Ser660), phospho-AMPK (Thr172), phospho-Akt (Ser473), phospho-ACC (Ser79), phospho-MEK1/2 (Ser217/212), phospho-ERK1/2 (Thr202/Tyr204), AMPK, Akt, ACC, MEK1/2, ERK1/2, phospho-VASP (Ser157), and H-89 were from Cell Signaling Technologies (Beverly, MA). Antibodies against total eNOS, total VASP, Caveolin-3, and phospho-eNOS (Ser633) were from BD Transduction Laboratories (Lexington, KY). Collagenase type 2 was from Worthington Biochemical (Lakewood, NJ). Compound C, PD98059 (a selective cell-permeable inhibitor of MAP kinase kinase [MEK]), “MEK1/2 inhibitor” (an inhibitor of the cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK1/2), and Calphostin C were from Calbiochem. Super Signal substrate for chemiluminescence detection and secondary antibodies conjugated to horseradish peroxidase were from Pierce. Tris-buffered saline and phosphate-buffered saline were from Boston Bioproducts (Ashland, MA). Laminin was from BD Bioscience (San Jose, CA). Minimum essential medium with Hank’s balanced salt solution and glutamine were from Gibco-BRL. Calf serum was from HyClone (Logan, UT). The AlexaFluor488 Annexin V/Dead cell apoptosis kit, Alexa Fluor-Green (488)-tagged goat anti-rabbit antibody and Alexa Fluor red (568)-tagged goat anti-mouse antibody were from Invitrogen/Molecular Probes. All other reagents were from Sigma (Plymouth Meeting, PA). Mouse line C57BL6/J was from Jackson Labs (Bar Harbor, ME). Cu2(FL2E) was synthesized as previously reported [28].

**Isolation of Adult Mouse Ventricular Myocytes**

All animal experimentation was performed according to protocols approved by the Harvard Medical School Committee on Use of Animals in Research. For these studies, 8–10-week-old C57BL6/J mice were lightly anesthetized with isofluorane, heparinized (50 U, ip), and sacrificed. The heart was quickly removed from the chest and retrogradely perfused through the aorta as described [29]. Cardiac myocyte isolation methods followed the described procedures [29], with minor modifications as previously reported [1]. In brief, enzymatic digestion was initiated by adding collagenase type 2 to the cardiac perfusion solution, followed by the stepwise introduction of CaCl2, after which the heart tissue was minced and the cells were dispersed by trituration. Subsequently, the cardiac myocytes were allowed to settle, and then washed, pelleted, counted, and plated.

**Cell Culture**

Cardiac myocytes were plated in laminin-coated 6-well culture dishes (50,000 rod-shaped cells per dish) in plating medium consisting of Minimum Essential Medium with Hank’s balanced salt solution, supplemented with calf serum (10% v/v), 2,3-butanedione monoxime (10 mM), penicillin-streptomycin (100 U/ml), glutamine (2 mM), and ATP (2 mM). After the cells were attached (~1 hour), the plating medium was changed to culture medium consisting of Minimum Essential Medium with Hank’s balanced salt solution, supplemented with bovine serum albumin (1 mg/ml), penicillin-streptomycin (100 U/ml), and glutamine (2 mM) and the cells were cultured for 4 hours.

**Measurements of Intracellular Ca2+ by Fura-2**

Intracellular calcium concentrations were monitored using electrically stimulated freshly isolated cardiac myocytes. In brief, coverslips of cardiac myocytes loaded with Fura-2/AM (1 μM, 20 min, room temperature) were used to monitor intracellular calcium transients. Fura-2 fluorescence was measured using an IonOptix spectrophotometer (HyperSwitch; IonOptix, Milton, MA, USA). Fura-2 was excited by light at 340-nm and 380-nm. A photomultiplier tube detected the emitted fluorescence at 510 nm. Experiments were performed at room temperature on the stage of an inverted microscope (Nikon, Tokyo, Japan), and myocytes were visualized using an air objective (S Fluor 40X). Field stimulation (5–10 V, 1 Hz) was accomplished using the MyoPacer (IonOptix). In all experiments, myocytes were kept in Tyrode’s solution (pH 7.45 with 1.0 mM CaCl2 added). A two-point Fura2 calibration was performed according to the method of Grynkiewicz et al. [30,31].

**Myocyte Sarcomere Shortening**

Myocytes were placed in a rapid change stimulation chamber on an inverted Nikon microscope stage and continuously bathed in Tyrode’s solution at room temperature, pH 7.45 with 1.0 mM CaCl2 added. Myocytes were field-stimulated (MyoPacer Field Stimulator, IonOptix, Milton, MA) at 1 Hz, 5–10 Volts. Sarcomere length was recorded with a video edge detector coupled to a camera (MyoCam-S, IonOptix). Sarcomere shortening analyses was performed using IonWizard Core Analysis software (IonOptix) in myocytes without any treatment and after 5 to 10 min of H2O2. In some studies, myocytes were pre-treated with nifedipine (100 μM) for at least 15 min before and during H2O2 treatment. Sarcomere shortening was expressed as percent shortening relative to the resting diastolic length.

**Intracellular Nitric Oxide Imaging**

Cardiac myocytes harvested from at least three independent preparations were analyzed. The signal from the NO sensor was
analyzed as the slope of the fluorescence increase observed following the addition of agonist or vehicle. Cells were cultured on cover slips and loaded with 5 μM CaF2(FL2E) [28] for 2 hours in Tyrode’s solution at 37°C and 2% CO2. Cover slips were then placed in an onset incubator (Tokai, Tokyo, Japan) on an Olympus IX81 inverted microscope equipped with an UPlan 40X/1.3 oil objective in a low-volume glass-covered recording chamber. Fluorescence signals were analyzed by using a Hamamatsu Orca CCD camera (Hamamatsu, Tokyo, Japan) at 470 nm. Viable rod-shaped cardiac myocytes with rectangular ends were selected by differential interface contrast imaging and then subjected to fluorescence imaging, following treatments as indicated.

Immunoblot Analyses

After drug treatments, cardiac myocytes were washed with PBS buffer and incubated for 10 minutes in lysis buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% Nonidet P-40; 0.25% sodium deoxycholate; 1 mM EDTA; 2 mM Na3VO4; 1 mM NaF; 10% glycerol; 2 μg/mL leupeptin; 2 μg/mL antipain; 2 μg/mL soybean trypsin inhibitor; and 2 μg/mL lima trypsin inhibitor). Cells were harvested by scraping. After separation by SDS-PAGE, proteins were electroblotted onto nitrocellulose membranes. After incubating the membranes in 5% nonfat dry milk in Tris-buffered saline with 0.1% (vol/vol) Tween 20 (TBST), membranes were incubated overnight in TBST containing 5% bovine serum albumin plus the specified primary antibody. After four washes (10 min each) with TBST, the membranes were incubated for one hour with a horseradish peroxidase-labeled goat anti-rabbit or anti-mouse immunoglobulin secondary antibody in TBST containing 1% milk. The membranes were washed four additional times in TBST, then incubated with a chemiluminescent reagent according to the manufacturer’s protocols (SuperSignal West Femto), and digitally imaged in a chemiluminescence imaging system (Alpha Innotech Corporation, San Leandro, CA). Quantitative analyses of the chemiluminescent signals were performed using an AlphaEaseFC software (Alpha Innotech, San Leandro, CA). For quantitative analyses of immunoblot experiments, the signal is normalized to the value obtained in the absence of added drug.

Immunohistochemistry

Cardiac myocytes plated on 8-well-chamber slides (Thermo Scientific) were fixed in 4% paraformaldehyde for 20 min, rinsed twice with PBS, permeabilized in 0.1% Triton X-100 for 45 min, and blocked with 10% goat serum overnight. Immunoreactive eNOS and caveolin-3 were co-localized using confocal microscopy. After incubating with both primary antibodies (in blocking solution at 4°C, overnight), samples were washed three times in PBS for 10 min. The eNOS primary antibody was localized by immunofluorescent detection with a secondary Alexa Fluor-Green (488)-tagged goat anti-rabbit antibody (1:200 dilution, 1 h incubation), and Cav-3 primary antibody was detected with a secondary Alexa Fluor red (568)-tagged goat anti-mouse antibody (1:200 dilution, 1 h incubation). Samples were washed three times in PBS for 10 min to remove excess secondary antibody and then mounted on slides using medium containing 4’,6-diamidino-2-phenylindole as nuclear counter stain. Microscopic analysis of samples was performed using an Olympus IX81 inverted microscope in conjunction with a DSI spinning disk confocal system equipped with a Hamamatsu Orca ER cooled-CCD camera. Images were acquired using a 40X/1.3 differential interference contrast oil immersion objective lens and analyzed using Metamorph software from Universal Imaging, Inc. (Downingtown, PA).

Measurement of Cell Viability and Apoptosis

Cardiac myocytes were plated on laminin-coated culture dishes in Tyrode’s solution at room temperature, pH 7.45 with 1.0 mM CaCl2 added. Cardiac myocytes were treated with varying concentrations of H2O2 for 15 minutes. Cell viability was determined by the ratio of rod-shaped to total cells. Apoptosis and necrosis were detected using an AlexaFluor488 annexin V/propidium iodide detection kit (Invitrogen/Molecular Probes). Briefly, cardiac myocytes were incubated with annexin V and propidium iodide for 10 minutes at room temperature. Dishes were photographed under both phase-contrast and fluorescence microscopy, and rod-shaped (viable), rounded (non-viable), and total cells were counted. Apoptotic cardiac myocytes were defined as annexin V-positive (green-stained cells) and necrotic myocytes as annexin V plus propidium iodide-positive cells (green- and red-stained cells).

Statistical Analysis

Mean values for individual experiments were expressed as means ± S.E. Statistical differences were assessed by ANOVA. A p value of less than 0.05 was considered significant.
Figure 6. Pathways controlling H2O2-promoted phosphorylation of MEK/ERK 1/2 and Akt. In panel A, cardiac myocytes were incubated with nifedipine (100 μM, 30 min) or vehicle, then treated with hydrogen peroxide (H2O2, 25 μM, 15 min) and analyzed in immunoblots probed with antibodies as shown. Panel B shows immunoblot analyses from cardiac myocytes incubated with BAPTA AM (60 μM, 30 min) or vehicle, then treated with H2O2. Panel C shows cardiac myocytes treated with calphostin C (1 μM, 30 min) prior treatment with H2O2. Below each representative immunoblot are shown the results of densitometric analyses from pooled data, documenting the changes in phospho-MEK1/2 (Ser217/221), phospho-ERK1/2 (Thr202/Tyr204) (left panels), and phospho-Akt Ser473 (right panels) plotted relative to the signal present in unstimulated cells. Each data point represents the mean ± S.E. derived from at least three independent experiments (n = 4 for nifedipine, 3 for BAPTA and 6 for Calphostin C); *indicates p < 0.05; **indicates p < 0.01 (ANOVA).

Figure 7. Effect of protein kinase A (PKA) inhibitor on H2O2-promoted eNOS phosphorylation. In panel A, cardiac myocytes were incubated with H89 (1 μM, 30 min) or vehicle, then treated with H2O2 (25 μM, 15 min) and analyzed in immunoblots probed with antibodies as shown. Below each representative immunoblot are shown the results of densitometric analyses from pooled data, documenting the changes in phospho-eNOS (Ser1177), and phospho-VASP (Ser157) plotted relative to the signals present in unstimulated cells. Each data point represents the mean ± S.E. derived from at least three independent experiments; *indicates p < 0.05 (ANOVA). Panel B shows representative immunoblots from experiments documenting the effects of A23187 (40 μM, 5 min) on cardiac myocyte protein phosphorylation responses. Panel C shows the results of immunoblots analyzed in lysates prepared from cells treated with phorbol 12-myristate 13-acetate (10 μM, 15 min). Cell lysates were analyzed in immunoblots probed with antibodies as indicated. The immunoblot images shown are representative of three independent experiments that yielded similar results. Below each immunoblot panel are the results of densitometric analyses from pooled data, showing the fold increase in protein phosphorylation (in arbitrary units), *indicates p < 0.05.
Figure 8. Scheme for H$_2$O$_2$-mediated regulation of eNOS signaling in cardiac myocytes. In this model, H$_2$O$_2$ activates the L-type Ca$^{2+}$ channel (LTCC), causing an elevation in [Ca$^{2+}$]$.i$. The increase in [Ca$^{2+}$]$.i$, promotes phosphorylation and activation of protein kinase PKC and Akt, which lead to an increase in eNOS phosphorylation. Activation of PKC is required for the phosphorylation of MEK1/2, ERK1/2, and AMPK, which in turn promote eNOS phosphorylation and an increase in NO synthesis. See the text for additional discussion.

doi:10.1371/journal.pone.0044627.g008

Supporting Information

Figure S1 In Panel A, cardiac myocytes were treated with hydrogen peroxide (H$_2$O$_2$, 25 μM) and analyzed in immunoblots probed with antibodies as shown. The immunoblots shown are representative of three independent experiments that yielded similar results. Panel B shows immunoblot analyses from cardiac myocytes incubated with PD98059 (50 μM, 30 min) or vehicle, then treated with H$_2$O$_2$ (25 μM, 15 min). Panel C shows representative immunoblot analyses from cells incubated with MEK1/2 inhibitor (1 μM, 30 min) or vehicle, then treated with H$_2$O$_2$. The immunoblots in panel B and C were probed with antibodies against phospho-Akt (Ser 473) or phospho-AMPK (Ser172). Panels D and E show results of pooled data corresponding to representative experiments shown in Figure 5 (panels C and D). In panel F, cardiac myocytes were treated with vehicle, H$_2$O$_2$ (25 μM), or H$_2$O$_2$ (500 μM) for 15 min and stained with annexin V and propidium iodide as described in the text. The two fluorescence channels were obtained sequentially; overlaying of the differential interference contrast image (DIC) and both fluorescence channels (annexin V and propidium iodide) is shown. Panel G shows the percentage of apoptotic (annexin V positive) and necrotic (annexin V + propidium iodide positive) cardiac myocytes. Panel H shows the percentage of viable (rod-shaped) and nonviable (round) cardiac myocytes. *indicates p<0.05; **indicates p<0.01; and ***indicates p<0.001 (ANOVA).

Acknowledgments

We thank Drs. Ruqin Kou, Yan Zhonghua, Ulf-Peter Apfel, and Maria Natalia Romero for critical discussions.

Author Contributions

Conceived and designed the experiments: JS HK TS SJL. TM. Performed the experiments: JS HK TS SS MP. Analyzed the data: JS HK TS SS MP SJL. TM. Contributed reagents/materials/analysis tools: MP SJL. Wrote the paper: JS HK SJL. TM.

References